Drug intelligence / Profile preview

Exosomes and Stem Cells (Inteligex collaboration)

Development stage: Preclinical
Lead developer: NurExone Biologic
Modality: Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal, Inhalation, Intravenous, Subcutaneous, Oral, Intrathecal, Intratumor, Intraarticular, Intraperitoneal

Overview

NurExone Biologic is developing a hybrid therapy in collaboration with Inteligex Inc. for the treatment of chronic spinal cord injury (SCI) and other traumatic injuries of the central nervous system (CNS). This program utilizes NurExone's proprietary ExoTherapy platform, which employs exosomes as nanocarriers to deliver stem cell-based treatments or stem-cell-derived components to injured tissues. The therapy is specifically designed to address the complex pathophysiology of chronic injury, including inflammation, cell death, and scar tissue formation, which differ from the challenges of acute injury. The program aims to promote neural repair and functional recovery. In 2023, the project received a grant from the Israel Innovation Authority as part of the Israel-Canada bilateral Eureka program and is currently in preclinical development.

Other names: exosome-based stem cell delivery system

Targets

PTEN (Phosphatase and tensin homolog deleted on chromosome ten)

Beyond the preview

Go deeper on Exosomes and Stem Cells (Inteligex collaboration).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exosomes and Stem Cells (Inteligex collaboration).

Explore the full profile